YTHDF1 and colorectal carcinoma: The genetic or pharmacological blockade of YTHDF1 effectively overcomes chemoresistance and suppresses CRC progression when combined with chemotherapeutic agents, highlighting YTHDF1 as a compelling therapeutic target for CRC.